



(51) International Patent Classification:
C12N 5/0783 (2010.01)

(21) International Application Number:
PCT/IB2021/058083

(22) International Filing Date:
04 September 2021 (04.09.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2013962.2 04 September 2020 (04.09.2020) GB

(71) Applicant: **GAMMADELTA THERAPEUTICS LIMITED** [GB/GB]; WestWorks, 195 Wood Lane, White City Place, London W12 7FQ (GB).

(72) Inventors: **RECALDIN, Timothy**; Gammadelta Therapeutics Ltd, Westworks 195 Wood Lane, White City Place, London W12 7FQ (GB). **SIMOES, Andre**; Gammadelta Therapeutics Ltd, Westworks 195 Wood Lane, White City Place, London W12 7FQ (GB). **NUSSBAUMER, Oliver**; Gammadelta Therapeutics Ltd, Westworks 195 Wood Lane, White City Place, London W12 7FQ (GB). **KO-**

VACS, Istvan; Gammadelta Therapeutics Ltd, Westworks 195 Wood Lane, White City Place, London W12 7FQ (GB).

PATEL, Mihil; Gammadelta Therapeutics Ltd, Westworks 195 Wood Lane, White City Place, London W12 7FQ (GB).

(74) Agent: **GOODALL, Scott** et al.; Sagittarius IP, Marlow International, Parkway, Marlow Buckinghamshire SL7 1YL (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: IMMUNOTHERAPY COMPOSITION

C




FIGURE 16

(57) Abstract: The invention relates to compositions comprising Natural Killer (NK) cells and $\gamma\delta$ T cells, particularly for use in adoptive immunotherapy. The invention also provides method for preparing such compositions which comprises contacting a sample with an anti-TCR delta variable 1 (anti-V δ 1) antibody.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*